Everence Capital Management Inc. Purchases New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Everence Capital Management Inc. acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,250 shares of the specialty pharmaceutical company’s stock, valued at approximately $277,000.

Several other hedge funds have also modified their holdings of the company. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its holdings in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC increased its position in shares of Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the period. Finally, Versant Capital Management Inc lifted its position in shares of Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 350 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ JAZZ opened at $122.54 on Wednesday. The company has a market capitalization of $7.41 billion, a P/E ratio of 17.26, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a 50 day simple moving average of $121.45 and a 200-day simple moving average of $113.89. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17.

Wall Street Analyst Weigh In

Several brokerages recently commented on JAZZ. HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Robert W. Baird lifted their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Piper Sandler reissued an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Finally, TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $177.00.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,253 shares of company stock valued at $1,001,434 over the last quarter. 4.20% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.